Scientists discover novel B cell that tempers autoimmunity
Infusions of purified IL-27 regulatory B cells (I27-Bregs) reduced symptoms in mouse models of multiple sclerosis and autoimmune uveitis.
List view / Grid view
Infusions of purified IL-27 regulatory B cells (I27-Bregs) reduced symptoms in mouse models of multiple sclerosis and autoimmune uveitis.
Dr Danilo Maddalo from Genentech outlines the main benefits of CRISPR within the clinical realm and highlights some of the safety concerns that must be considered before CRISPR products reach patients.
All mice infected with anthrax spores were completely protected after treatment with a pegylated enzyme known as PEG-CapD-CPS334C.
The new research shows how interleukin-17a (IL-17a) can alter the trajectory of immune system development and cause gut inflammation.
The new nanoparticle uses a peptide to target the vascular cell adhesion molecule 1 and reduced the size of vascular lesions in a mouse study.
The new nanoparticle adjuvant improved antibody production following vaccination against HIV, diphtheria and influenza in mouse models.
The exciting new study demonstrates how the technology could be used to improve animal welfare in scientific research and agriculture.
Scientists used a new screen to identify FAM72A as a cause of mutagenesis that affects antibody development in COVID-19 and cancer.
Scientists identify a drug candidate to minimise erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
A new study prevented the growth of metastatic tumours in mice by forcing cancer cells into a dormant state, pointing to novel treatments.
A new study links tumour necrosis factor seen in rheumatoid arthritis with T cell dysfunction, potentially leading to new therapies.
The CRISPR-based therapy called EBT-101 excised HIV proviral DNA from the genomes of different cells and tissues in human cells and mice.
Removing stress hormones in mouse models restored proper function to immune cells and epithelial cells, pointing to new Crohn's treatments.
The study uncovered disordered signalling in the brain's cerebellum, offering a novel therapeutic target for Prader Willi syndrome.
Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.